1.0T开放型磁共振引导经皮穿刺125I放射性粒子植入治疗晚期胰腺癌

doi:10.6040/j.issn.1671-7554.0.2016.1476

摘要/Abstract

摘要： 目的评价1.0T开放式MRI引导下经皮¹²⁵I放射性粒子植入治疗不可手术切除的晚期胰腺癌的可行性、安全性与有效性。方法选取31例无法外科手术切除的晚期胰腺癌患者,术前行MRI引导下穿刺活检,病理证实为胰腺癌。制定治疗计划系统(TPS),设定处方剂量(PD)120~160 Gy,D90>90%PD,V100>90%,V200<50%,在1.0T开放式磁共振引导下,结合呼吸门控技术行放射性¹²⁵I粒子植入。术后24 h内实施TPS剂量验证。结果 31例患者均顺利穿刺并按术前计划植入¹²⁵I粒子,手术成功率100%。术后TPS验证,D90范围91%~112%PD,V100范围92%~106%,V200范围21%~49%。术后第1、3、6、12个月复查,以后每1年复查1次,中位生存时间为14.7个月,Ⅲ期和Ⅳ期的的中位生存时间分别为16.3个月和5.9个月。有效率83.8%,局部控制率93.5%。疼痛缓解有效率91.6%。未见胰腺炎、胰瘘、肠瘘、腹腔出血等严重并发症。结论 1.0T磁共振引导经皮放射性¹²⁵I粒子植入治疗不可手术切除的晚期胰腺癌可行、且安全有效。

关键词: ¹²⁵I粒子, 磁共振成像, 不可手术切除, 胰腺癌

Abstract: Objective To evaluate the feasibility, safety and efficacy of 1.0T open MRI-guided ¹²⁵I seeds percutaneous implantation in the treatment of unresectable advanced pancreatic cancer. Methods A group of 31 patients with confirmed unresectable advanced pancreatic cancer were enrolled. The treatment plan was designed with treatment plan system(TPS)before implantation. With prescription dose(PD)being 120~160 Gy, D90>90%PD, V100>90%, V200<50%, under the 1.0T open MRI guidance, ¹²⁵I seeds were implanted. Dosimetric verification was conducted within 24 h after surgery. Results All 31 procedures were successful. After implantation, TPS showed D90, V100 and V200 ranged 91%-112%PD, 92%-106%, and 21%-49%, respectively. The patients were rechecked 1, 3, 6 and 12 months after operation, and after that once a year. The median survival was 14.7, 16.3 and 5.9 months for the whole group, for patients with stage Ⅲ cancer and stage Ⅳ cancer. The effective rate was 83.8%, local control rate was 93.5%, and pain relief rate was 91.6%. No serious complications such as pancreatitis, pancreatic fistula, intestinal fistula and hemorrhage were observed. Conclusion 1.0T open MRI-guided ¹²⁵I seeds percutaneous implantation is safe, feasible and effective for unresectable advanced pancreatic cancer.

Key words: ¹²⁵I seeds, Unresectable, Pancreatic cancer, Magnetic resonance imaging

中图分类号:

R735.9

许玉军,柳明,何祥萌,李成利. 1.0T开放型磁共振引导经皮穿刺¹²⁵I放射性粒子植入治疗晚期胰腺癌[J]. 山东大学学报（医学版）, 2017, 55(2): 21-25.

XU Yujun, LIU Ming, HE Xiangmeng, LI Chengli. 1.0T open MRI-guided ¹²⁵I seeds percutaneous implantation for advanced pancreatic cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 21-25.

参考文献

[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
[2] Zhang B, Dong Y, Liu J, et al. Immunotherapy for patients with advanced pancreatic carcinoma: a promising treatment[J]. Oncotarget, 2016, 15. doi:18632/oncotarget.13968.[Epub ahead of print].
[3] Ceha HM, van Tienhoven G, Gouma DJ, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma[J]. Cancer, 2000, 89(11): 2222-2229.
[4] Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8): 1183-1190.
[5] Niu H, Zhang X, Wang B, et al, The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer[J]. Tumour Biol, 2016, 37(2): 2219-2223.
[6] Wang CF, Zhao P, Li YX, et al, Role of ¹²⁵I seed implantation in treatment of unresectable pancreatic cancer[J]. Zhonghua Yi Xue Za Zhi, 2010, 90(2): 92-95.
[7] Abrams RA, Lowy AM, OReilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement[J]. Ann Surg Oncol, 2009, 16(7): 1751-1756.
[8] Wang Z, Lu J, Liu L,et al. Clinical application of CT-guided(125)I seed interstitial implantation for local recurrent rectal carcinoma[J]. Radiat Oncol, 2011, 6: 138. doi: 10.1186/1748-717X-6-138.
[9] Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8): 437-447.
[10] Gillen S, Schuster T, Friess H, et al. Palliative resections versus palliative bypass procedures in pancreatic cancer-a systematic review[J]. Am J Surg, 2012, 203(4): 496-502.
[11] Sugyo A, Tsuji AB, Sudo H, et al. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model[J]. Nucl Med Commun, 2015, 36(3): 286-294.
[12] Xu JB, Yang XC, Guo JH, et al. Serum nerve growth factor level indicates therapeutic efficacy of ¹²⁵I seed implantation in advanced pancreatic adenocarcinoma[J]. Eur Rev Med Pharmacol Sci, 2015, 19(18): 3385-3390.
[13] Bodner WR, Hilaris BS, Mastoras DA. Radimion therapy in pancreatic cancer: current practice and future trends[J]. J Clin Gastroenterol, 2000, 30(3): 230-233.
[14] Liu K, Ji B, Zhang W, et al. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer[J]. Int J Med Sci, 2014, 11(9):893-896.
[15] Tanimoto R, Bekku K, Ebara S, et al. The impact of neoadjuvant hormone therapy on the permanent 125I-seed brachytherapy for low-or intermediate-risk prostate cancer[J]. J Clin Oncol, 2012, 30(5_suppl):201.
[16] Huang ZM, Pan CC, Wu PH, et al. Efficacy of minimally invasive therapies on unresectable pancreatic cancer[J]. Chin J Cancer, 2013, 32(6): 334-341.
[17] Liu B, Zhou T, Geng J, et al. Percutaneous computed tomography guided iodine 125 seeds implantation for unresectable pancreatic cancer[J]. Indian J Cancer, 2015, 52(2): 69-74.
[18] Li YF, Liu ZQ, Zhang YS, et al. Implantation of radioactive(125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: a retrospective study[J]. J Huazhong Univ Technolog Med Sci, 2016, 36(2): 205-210.
[19] Wang H, Wang J, Jiang Y, et al. The investigation of ¹²⁵I seed implantation as a salvage modality for unresectable pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2013, 32: 10. doi: 10.1186/1756-9966-32-106.
[20] Wang J, Jiang Y, Li J, et al. Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2009, 28: 88. doi: 10.1186/1756-9966-28-88.
[21] Liu M, Huang J, Xu Y, et al. MR-guided percutaneous biopsy of solitary pulmonary lesions using a 1.0-T open high-field MRI scanner with respiratory gating[J]. Eur Radiol, 2016 Aug 11.[Epub ahead of print].

相关文章 15

[1]	金晨曦,沈薇,李娜,孙建锋,杨驰,郭泾. ADDWoR关节镜下盘复位术盘-髁运动的定量分析[J]. 山东大学学报 (医学版), 2025, 63(7): 54-61.
[2]	祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88.
[3]	杜凯豪,侯立朝,东小鸽,薛伟伟,何洁洁,罗兰明慧,蒋威,汪占金,王展. 东亚人肠道菌群与胰腺癌关系:基于孟德尔随机化方法的遗传学证据[J]. 山东大学学报 (医学版), 2025, 63(12): 44-52.
[4]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[5]	刘小文,曹永泉,侯明源,于德新. EOB-MRI多定量参数对肝胆期乏血供低信号结节进展风险的评估价值[J]. 山东大学学报 (医学版), 2024, 62(4): 31-39.
[6]	吴思雨,沈业隆,王锡明. 影像组学预测原发性中枢神经系统淋巴瘤的Ki-67标记指数[J]. 山东大学学报 (医学版), 2024, 62(11): 67-72.
[7]	靳新娟,左立平,邓展昊,李安宁,于德新. MRI影像组学对135例肝癌耐药蛋白PFKFB3的预测价值[J]. 山东大学学报 (医学版), 2023, 61(6): 79-86.
[8]	王磊,张帅,刘钢,由胜男,王植,朱珊,陈超,马信龙,杨强. MRI诊断140例腰椎智能网络自动检测分型MCs方法的比较[J]. 山东大学学报 (医学版), 2023, 61(3): 71-79.
[9]	杨咏青,赵鹏,汪玉,马文静,田迷迷,程亚旎,祖璐,林祥涛. 细胞外容积分数对62例不同病理类型肺癌的诊断价值[J]. 山东大学学报 (医学版), 2023, 61(2): 88-94.
[10]	靳新娟,蔡大幸,范金蕾,邓展昊,李楠,于德新,李安宁. 显微镜高分辨率MRI鉴别皮肤良、恶性局灶隆起性结节[J]. 山东大学学报 (医学版), 2023, 61(12): 51-61.
[11]	赵恩举,赵硕,郭云亮,王锡明. 282例颈动脉钙化与脑小血管病MRI总负荷评分的关联性[J]. 山东大学学报 (医学版), 2023, 61(1): 38-44.
[12]	陶国伟,王芳,董向毅,徐亚瑄,赵琳丽,胡蓓蓓. 子宫腺肌病的超声与MRI诊断及进展[J]. 山东大学学报 (医学版), 2022, 60(7): 56-65.
[13]	苑宝文,王沛,黄蔚. 组蛋白去乙酰化酶SIRT1对胰腺癌代谢的调控作用[J]. 山东大学学报 (医学版), 2022, 60(3): 1-12.
[14]	冯宝民,王舟,徐晗,李佳存,于乔文,修建军. 抗髓鞘少突胶质细胞糖蛋白IgG抗体相关疾病临床及影像特征[J]. 山东大学学报 (医学版), 2022, 60(3): 45-50.
[15]	左立平,蒋丰洋,周斌彬,范金蕾,梁永锋,邓展昊,于德新. 术前MRI在预测169例肝细胞肝癌微血管侵犯及早期复发的价值[J]. 山东大学学报 (医学版), 2022, 60(3): 89-95.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

1.0T开放型磁共振引导经皮穿刺¹²⁵I放射性粒子植入治疗晚期胰腺癌

1.0T open MRI-guided ¹²⁵I seeds percutaneous implantation for advanced pancreatic cancer

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

多维度评价

本文评价

推荐阅读 0